Elevated Plasma Level of Soluble F11 Receptor/Junctional Adhesion Molecule-A (F11R/JAM-A) in Hypertension

Ong, Kwok Leung; Leung, R; Babińska, Anna; Salifu, Moro O.; Ehrlich, Yigal H.; Kornecki, Elizabeth; Wong, LC; Tso, Annette W.K.; Cherny, Stacey S.; Sham, Pak C.; Lam, Tai Hing; Lam, Karen S.L.; Cheung, Bernard M Y

doi:10.1038/ajh.2009.23

Cited by 37 publications

(35 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, when we examined the changes of plasma soluble JAM-A before and after surgical resection of HNSCC, the values of plasma soluble JAM-A in some HNSCC patients after surgical resection significantly reduced compared to the before (data not shown). As the extracellular domain of JAM-A has a potential cleavage site [19], soluble JAM-A is detected in the serum and is associated with inflammation, angiogenesis, hypertension [20], ischemia and atherosclerosis [21]. Although the plasma-soluble JAM-A should be measured in more samples from patients, including those with other diseases, it is possible that the plasma-soluble JAM-A expression in HNSCC patients may contribute to serum-based diagnosis of HNSCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Circulating soluble JAM-A is associated with inflammation, angiogenesis, hypertension [20], ischemia and atherosclerosis [21]. However, the changes of plasma soluble JAM-A remain unclear during carcinogenesis.…”

Section: Introductionmentioning

confidence: 99%

Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma

et al. 2016

View full text Add to dashboard Cite

show abstract

“…!4.10 pmol/l) and a level equal to the limit of detection divided by the square root of two was imputed (32). Plasma fibrinogen was measured using a Cobas Fibro instrument (Roche Diagnostics) as described previously (33). Plasma high-sensitivity CRP was measured with an in-house sandwich ELISA established in our laboratory as described previously (34,35).…”

Section: Measurement Of Plasma Adm and Other Biomarkersmentioning

confidence: 99%

Plasma adrenomedullin level is related to a single nucleotide polymorphism in the adrenomedullin gene

Cheung

Ong²,

Tso³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Adrenomedullin (ADM) plays an important role in inflammation and is a marker of future cardiovascular events. We studied common single nucleotide polymorphisms (SNPs) in the gene encoding ADM and their relationship with the plasma levels of ADM and other inflammatory markers. Design and methods: Plasma ADM, interleukin 6 (IL6), fibrinogen, and C-reactive protein (CRP) were measured in 476 subjects from the population-based Hong Kong Cardiovascular Risk Factor Prevalence Study-2. Four tag SNPs in ADM were genotyped. Results: Plasma ADM level increased with decreasing plasma IL6 level (bZK0.116, PZ0.014). Plasma ADM level was not related to plasma levels of CRP and fibrinogen, and other clinical characteristics, except age (PZ0.049). The four SNPs, rs3814700, rs11042725, rs34354539, and rs4910118, had minor allele frequencies of 31.1, 28.7, 33.8, and 23.4% respectively. Carriers of the minor allele of rs4910118 had a mean plasma ADM level that was 10.5% (95% confidential interval: 2.5-17.8%) lower than the non-carriers (bZK0.115, PZ0.011). Haplotype analysis revealed a similar significant association with plasma ADM (PZ0.040). In multivariate analysis, the presence of the minor allele of rs4910118, but not plasma IL6, was independently associated with plasma ADM (PZ0.010). Conclusion: Plasma ADM correlates with plasma IL6 level, consistent with its role in inflammation. It is related to an SNP common in Chinese, independent of other covariates. ADM genotype should be included in future studies of cardiovascular risk prediction.

show abstract

“…Increased sJAM-A plasma or serum levels compared to healthy controls were described in patients with coronary artery disease, arterial hypertension, systemic sclerosis, and renal insufficiency undergoing hemodialysis [19], [20], [21], [22]. Two different groups recently identified human EC, namely dermal microvascular EC (HDMEC) and umbilical vein EC (HUVEC), as a cellular source of sJAM-A.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Soluble Junctional Adhesion Molecule-A as a Biomarker of Human Brain Endothelial Barrier Breakdown

et al. 2010

View full text Add to dashboard Cite

BackgroundAn inducible release of soluble junctional adhesion molecule-A (sJAM-A) under pro-inflammatory conditions was described in cultured non-CNS endothelial cells (EC) and increased sJAM-A serum levels were found to indicate inflammation in non-CNS vascular beds. Here we studied the regulation of JAM-A expression in cultured brain EC and evaluated sJAM-A as a serum biomarker of blood-brain barrier (BBB) function.Methodology/Principal FindingsAs previously reported in non-CNS EC types, pro-inflammatory stimulation of primary or immortalized (hCMEC/D3) human brain microvascular EC (HBMEC) induced a redistribution of cell-bound JAM-A on the cell surface away from tight junctions, along with a dissociation from the cytoskeleton. This was paralleled by reduced immunocytochemical staining of occludin and zonula occludens-1 as well as by increased paracellular permeability for dextran 3000. Both a self-developed ELISA test and Western blot analysis detected a constitutive sJAM-A release by HBMEC into culture supernatants, which importantly was unaffected by pro-inflammatory or hypoxia/reoxygenation challenge. Accordingly, serum levels of sJAM-A were unaltered in 14 patients with clinically active multiple sclerosis compared to 45 stable patients and remained unchanged in 13 patients with acute ischemic non-small vessel stroke over time.ConclusionSoluble JAM-A was not suited as a biomarker of BBB breakdown in our hands. The unexpected non-inducibility of sJAM-A release at the human BBB might contribute to a particular resistance of brain EC to inflammatory stimuli, protecting the CNS compartment.

show abstract

Elevated Plasma Level of Soluble F11 Receptor/Junctional Adhesion Molecule-A (F11R/JAM-A) in Hypertension

Abstract: These results further support a role of F11 receptor in the pathophysiology of human hypertension.

Cited by 37 publications

References 27 publications

Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma

Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma

Plasma adrenomedullin level is related to a single nucleotide polymorphism in the adrenomedullin gene

Evaluation of Soluble Junctional Adhesion Molecule-A as a Biomarker of Human Brain Endothelial Barrier Breakdown

Contact Info

Product

Resources

About